FY2025 · ended Dec 31, 2025 · Revenue $51.66M, +12.4% YoY · Filed Mar 31, 2026
Lensar, Inc. (LNSR) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $51.7 million and a net loss of $34.3 million. Free cash flow was -$14.9 million. As of Jun 30, 2026 it held $13.6 million in cash and investments and $2.4 million in total debt.
Revenue (TTM)
$53.56M
+4.6% vs year-ago TTM
Net income (TTM)
$34.70M
+170.4% vs year-ago TTM
Operating cash flow (TTM)
$-7.29M
-42.3% vs year-ago TTM
Free cash flow (TTM)
$-7.33M
-40.1% vs year-ago TTM
EPS (TTM)
$0.82
+119.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
12.10M
+0.1% vs prior year
Net cash
$11.18M
as of Jun 30, 2026
Operating margin
-15.2%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- LNSR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Orlando, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1320350
- Former names
- LensAR Inc (until Jan 14, 2015); LaserSoft Vision Inc (until Jun 16, 2006)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $51.7M | $46.0M | $35.7M | $29.4M | $29.5M |
| Operating income | -$24.6M | -$10.7M | -$12.2M | -$20.2M | -$19.7M |
| Net income | -$34.3M | -$31.4M | -$14.4M | -$19.9M | -$19.6M |
| Diluted EPS | -$2.87 | -$2.73 | -$1.31 | -$1.96 | — |
| Operating cash flow | -$14.8M | -$2.3M | -$9.7M | -$14.9M | -$9.0M |
| Free cash flow | -$14.9M | -$2.4M | -$9.9M | -$15.0M | -$9.3M |
| Total assets | $71.4M | $66.3M | $69.6M | $55.8M | $66.5M |
| Total liabilities | $83.7M | $47.7M | $22.4M | $13.9M | $11.6M |
| Stockholders' equity | -$26.0M | $4.9M | $33.4M | $42.0M | $54.9M |
| Cash and investments | $18.0M | $22.5M | $24.6M | $14.7M | $31.6M |
| Total debt | $2.7M | $2.6M | $2.3M | $2.8M | $3.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 10, 2026 | Aug 4, 2026 |
| ARS | Annual report to shareholders | Jun 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
May 29, 2026 | May 25, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
All 327 Lensar, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.